WuXi Biologics

WuXi Biologics Secures ISO 13485 Certification for Drug–Device Development and Manufacturing

WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug–Device Combination Product Development and Manufacturing WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced…

Read MoreWuXi Biologics Secures ISO 13485 Certification for Drug–Device Development and Manufacturing

Pangea Pharmaceuticals Launches Sdamlo™, First FDA-Approved Amlodipine Oral Solution Powder in the U.S.

Pangea Pharmaceuticals Announces U.S. Launch of Sdamlo™, the First and Only FDA-Approved, Amlodipine Powder for Oral Solution Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant…

Read MorePangea Pharmaceuticals Launches Sdamlo™, First FDA-Approved Amlodipine Oral Solution Powder in the U.S.